Cleavage-stage human embryo arrest, is it embryo genetic composition or others?


Journal

Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627

Informations de publication

Date de publication:
17 Mar 2022
Historique:
received: 11 02 2022
accepted: 04 03 2022
entrez: 18 3 2022
pubmed: 19 3 2022
medline: 29 3 2022
Statut: epublish

Résumé

Embryo transfer is a crucial step in IVF cycle, with increasing trend during the last decade of transferring a single embryo, preferably at the blastocyst stage. Despite increasing evidence supporting Day 5 blastocyst-stage transfer, the optimal day of embryo transfer remains controversial. The crucial questions are therefore, whether the mechanisms responsible to embryos arrest are embryo aneuploidy or others, and whether those embryos arrested in-vitro between the cleavage to the blastocyst stage would survive in-vivo if transferred on the cleavage-stage. We therefore aim to explore whether aneuploidy can directly contribute to embryo development to the blastocyst stage. Thirty Day-5 embryos, that their Day-3 blastomere biopsy revealed a single-gene defect, were donated by 10 couples undergoing preimplantation genetic testing treatment at our center. Affected high quality Day-3 embryos were cultured to Day-5, and were classified to those that developed to the blastocyst-stage and those that were arrested. Each embryo underwent whole genome amplification. Eighteen (60%) embryos were arrested, did not develop to the blastocyst stage and 12 (40%) have developed to the blastocyst stage. Nineteen embryos (63.3%) were found to be euploid. Of them, 12 (66.6%) were arrested embryos and 7 (58.3%) were those that developed to the blastocyst-stage. These figures were not statistically different (p = 0.644). Our observation demonstrated that the mechanism responsible to embryos arrest in vitro is not embryo aneuploidy, but rather other, such as culture conditions. If further studies will confirm that Day-5 blastocyst transfer might cause losses of embryos that would have been survived in vivo, cleavage-stage embryo transfer would be the preferred timing. This might reduce the cycle cancellations due to failure of embryo to develop to the blastocyst stage and will provide the best cumulative live birth-rate per started cycle.

Identifiants

pubmed: 35300691
doi: 10.1186/s12958-022-00925-2
pii: 10.1186/s12958-022-00925-2
pmc: PMC8928691
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52

Informations de copyright

© 2022. The Author(s).

Références

Fertil Steril. 2013 Dec;100(6):1695-703
pubmed: 24034939
Prenat Diagn. 2000 Jul;20(7):552-60
pubmed: 10913953
Hum Reprod. 2019 Jan 01;34(1):181-192
pubmed: 30418565
Hum Reprod. 2017 Apr 1;32(4):853-859
pubmed: 28166330
Ultrasound Obstet Gynecol. 2017 May;49(5):583-591
pubmed: 27731533
Fertil Steril. 2002 Jun;77(6):1300-1
pubmed: 12057748
Fertil Steril. 2019 Dec;112(6):1071-1079.e7
pubmed: 31551155
Fertil Steril. 2009 Sep;92(3):890-896
pubmed: 18829021
Cochrane Database Syst Rev. 2016 Jun 30;(6):CD002118
pubmed: 27357126
N Engl J Med. 2021 Nov 25;385(22):2047-2058
pubmed: 34818479
Hum Reprod. 2004 Sep;19(9):2174
pubmed: 15756718
Fertil Steril. 2016 Aug;106(2):244-50
pubmed: 27421614
J Ovarian Res. 2014 Jun 13;7:65
pubmed: 24955133
Reprod Biol Endocrinol. 2020 Oct 6;18(1):98
pubmed: 33023576
Reprod Biomed Online. 2019 Dec;39(6):916-923
pubmed: 31685365
Reproduction. 2004 Sep;128(3):281-91
pubmed: 15333779
Hum Reprod Update. 2014 Jul-Aug;20(4):571-81
pubmed: 24667481
Nat Commun. 2020 Aug 10;11(1):3987
pubmed: 32778678
Fertil Steril. 1998 Jan;69(1):84-8
pubmed: 9457939

Auteurs

Raoul Orvieto (R)

Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), 56261, Ramat Gan, Israel. raoul.orvieto@sheba.health.gov.il.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. raoul.orvieto@sheba.health.gov.il.
The Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. raoul.orvieto@sheba.health.gov.il.

Anat Jonish-Grossman (A)

Danek Gertner Institute of Human Genetics, Sheba Medical Center, 56261, Ramat-Gan, Israel.

Sharon Avhar Maydan (SA)

Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), 56261, Ramat Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Meirav Noach-Hirsh (M)

Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), 56261, Ramat Gan, Israel.

Olga Dratviman-Storobinsky (O)

Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), 56261, Ramat Gan, Israel.

Adva Aizer (A)

Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), 56261, Ramat Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH